J. Safra Sarasin Holding AG purchased a new position in shares of Waters Co. (NYSE:WAT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 894 shares of the medical instruments supplier's stock, valued at approximately $332,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd acquired a new stake in Waters during the 4th quarter worth $28,000. Bank of Jackson Hole Trust purchased a new position in Waters in the 4th quarter valued at $34,000. Fortitude Family Office LLC increased its stake in Waters by 235.7% in the 4th quarter. Fortitude Family Office LLC now owns 94 shares of the medical instruments supplier's stock valued at $35,000 after buying an additional 66 shares during the period. Steward Partners Investment Advisory LLC boosted its holdings in shares of Waters by 129.3% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 94 shares of the medical instruments supplier's stock valued at $35,000 after acquiring an additional 53 shares in the last quarter. Finally, Murphy & Mullick Capital Management Corp acquired a new position in shares of Waters during the fourth quarter worth about $42,000. Hedge funds and other institutional investors own 94.01% of the company's stock.
Waters Trading Down 0.8 %
Shares of WAT stock traded down $2.74 during trading hours on Friday, hitting $337.96. 252,623 shares of the company were exchanged, compared to its average volume of 475,445. The firm has a fifty day moving average of $355.96 and a 200 day moving average of $370.45. The company has a quick ratio of 0.65, a current ratio of 0.94 and a debt-to-equity ratio of 1.14. Waters Co. has a 1 year low of $279.24 and a 1 year high of $423.56. The firm has a market cap of $20.11 billion, a PE ratio of 31.56, a PEG ratio of 3.79 and a beta of 1.04.
Waters (NYSE:WAT - Get Free Report) last issued its earnings results on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.02 by $0.08. Waters had a return on equity of 46.31% and a net margin of 21.56%. Analysts expect that Waters Co. will post 12.86 earnings per share for the current year.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on WAT. JPMorgan Chase & Co. increased their target price on Waters from $380.00 to $390.00 and gave the stock a "neutral" rating in a research note on Thursday, March 6th. KeyCorp raised shares of Waters from a "sector weight" rating to an "overweight" rating and set a $460.00 price target on the stock in a research note on Monday, March 31st. Barclays decreased their price objective on shares of Waters from $400.00 to $350.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. UBS Group boosted their target price on Waters from $405.00 to $410.00 and gave the stock a "neutral" rating in a research report on Thursday, February 13th. Finally, Robert W. Baird dropped their price target on Waters from $407.00 to $355.00 and set an "outperform" rating for the company in a research report on Tuesday. Ten equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $392.13.
Get Our Latest Analysis on WAT
Waters Profile
(
Free Report)
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
See Also

Before you consider Waters, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list.
While Waters currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.